Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study of ALPN-202 Combined With PD-1 Inhibition in Subjects With Advanced Malignancies (NEON-2)

NCT04920383 is registered in ClinicalTrials.gov with Alpine Immune Sciences, Inc. as lead sponsor.

NCT NCT04920383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04920383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study of ALPN-202 Combined With PD-1 Inhibition in Subjects With Advanced Malignancies (NEON-2)
Lead sponsor
Alpine Immune Sciences, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
June 22, 2021
Completion date
February 28, 2023
Enrollment
29 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, lymphoma